Related references
Note: Only part of the references are listed.Rotenone induces regionally distinct α-synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl/6 mice
Savannah M. Rocha et al.
NEUROBIOLOGY OF DISEASE (2022)
Parkinson disease-associated cognitive impairment
Dag Aarsland et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
The genetic architecture of Parkinson's disease
Cornelis Blauwendraat et al.
LANCET NEUROLOGY (2020)
Modeling Parkinson's Disease With the Alpha-Synuclein Protein
Monica Gomez-Benito et al.
FRONTIERS IN PHARMACOLOGY (2020)
Clinical and Imaging Markers of Prodromal Parkinson's Disease
Eldbjorg Hustad et al.
FRONTIERS IN NEUROLOGY (2020)
Differential protein expression in diverse brain areas of Parkinson's and Alzheimer's disease patients
A. R. Esteves et al.
SCIENTIFIC REPORTS (2020)
Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson's Disease
E. Maruthi Prasad et al.
ANTIOXIDANTS (2020)
Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors
Jan Korbecki et al.
INFLAMMATION RESEARCH (2019)
Circuit Mechanisms of Parkinson's Disease
Matthew M. McGregor et al.
NEURON (2019)
Parkinson's Disease and the Environment
Nicole Ball et al.
FRONTIERS IN NEUROLOGY (2019)
α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies
Michael X. Henderson et al.
NEUROSCIENCE LETTERS (2019)
An Investigation on the Clinical Features and Neurochemical Changes in Parkinson's Disease With Depression
Teng-Hong Lian et al.
FRONTIERS IN PSYCHIATRY (2019)
Cell Biology and Pathophysiology of α-Synuclein
Jacqueline Burre et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Mild Cognitive Impairment in Parkinson's Disease-What Is It?
Rimona S. Weil et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2018)
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Nadia Bougarne et al.
ENDOCRINE REVIEWS (2018)
Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis
Vittorio Calabrese et al.
FREE RADICAL BIOLOGY AND MEDICINE (2018)
Risk factors for non-motor symptoms in Parkinson's disease
Johan Marinus et al.
LANCET NEUROLOGY (2018)
On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Nicolas Giguere et al.
FRONTIERS IN NEUROLOGY (2018)
Dysregulation of bcl-2 enhanced rotenone-induced -synuclein aggregation associated with autophagic pathways
Yan Chen et al.
NEUROREPORT (2018)
Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease
Paulina Troncoso-Escudero et al.
FRONTIERS IN NEUROLOGY (2018)
Epidemiology of Parkinson's disease
Ole-Bjorn Tysnes et al.
JOURNAL OF NEURAL TRANSMISSION (2017)
Non-motor features of Parkinson disease
Anthony H. V. Schapira et al.
NATURE REVIEWS NEUROSCIENCE (2017)
Parkinson's Disease Subtypes Identified from Cluster Analysis of Moto rand Non-motor Symptoms
Jesse Mu et al.
FRONTIERS IN AGING NEUROSCIENCE (2017)
Subcutaneous rotenone rat model of Parkinson's disease: Dose exploration study
Zhen-Nian Zhang et al.
BRAIN RESEARCH (2017)
Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo
Mohammad A. Esmaeili et al.
HUMAN MOLECULAR GENETICS (2016)
The epidemiology of Parkinson's disease: risk factors and prevention
Alberto Ascherio et al.
LANCET NEUROLOGY (2016)
The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis
Lauren Hirsch et al.
NEUROEPIDEMIOLOGY (2016)
Epidemiology of Parkinson Disease
Andrea Lee et al.
NEUROLOGIC CLINICS (2016)
The role of PPAR activation during the systemic response to brain injury
Patrick Losey et al.
JOURNAL OF NEUROINFLAMMATION (2015)
The molecular mechanism of rotenone-induced α-synuclein aggregation: Emphasizing the role of the calcium/GSK3β pathway
Yu-he Yuan et al.
TOXICOLOGY LETTERS (2015)
Alterations in neuronal activity in basal ganglia-thalarnocortical circuits in the parkinsonian state
Adriana Galvan et al.
FRONTIERS IN NEUROANATOMY (2015)
Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?
Amy Reeve et al.
AGEING RESEARCH REVIEWS (2014)
Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine
Janaina K. Barbiero et al.
BEHAVIOURAL BRAIN RESEARCH (2014)
Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin
Ronise M. Santiago et al.
BEHAVIOURAL BRAIN RESEARCH (2014)
Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats
Taysa B. Bassani et al.
BRAIN RESEARCH (2014)
PPAR-α. agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease
Janaina K. Barbiero et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2014)
Neuroprotective Potential of Peroxisome Proliferator Activated Receptor-α Agonist in Cognitive Impairment in Parkinson's Disease: Behavioral, Biochemical, and PBPK Profile
Dedeepya Uppalapati et al.
PPAR RESEARCH (2014)
Parkinson's disease: animal models and dopaminergic cell vulnerability
Javier Blesa et al.
FRONTIERS IN NEUROANATOMY (2014)
Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling Pathway
Ning Zhang et al.
ONCOTARGET (2014)
The Role of Fibrate Treatment in Dyslipidemia: An Overview
Niki Katsiki et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Beneficial Effect of Vitamin E in Rotenone Induced Model of PD: Behavioural, Neurochemical and Biochemical Study
Neha Sharma et al.
Experimental Neurobiology (2013)
A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson's Disease
Shams Tabrez et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2012)
Clofibrate PPARα Activation Reduces Oxidative Stress and Improves Ultrastructure and Ventricular Hemodynamics in No-flow Myocardial Ischemia
Luz Ibarra-Lara et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2012)
Depression in Parkinson disease-epidemiology, mechanisms and management
Dag Aarsland et al.
NATURE REVIEWS NEUROLOGY (2012)
NEUROTOXIN-BASED MODELS OF PARKINSON'S DISEASE
J. Bove et al.
NEUROSCIENCE (2012)
Behavioral, Neurochemical and Histological Alterations Promoted by Bilateral Intranigral Rotenone Administration: A New Approach for an Old Neurotoxin
Camila G. Moreira et al.
NEUROTOXICITY RESEARCH (2012)
Fenofibrate Reduces Mortality and Precludes Neurological Deficits in Survivors in Murine Model of Japanese Encephalitis Viral Infection
Neha Sehgal et al.
PLOS ONE (2012)
Neuroprotective Activities of Palmitoylethanolamide in an Animal Model of Parkinson's Disease
Emanuela Esposito et al.
PLOS ONE (2012)
Characterization of motor, depressive-like and neurochemical alterations induced by a short-term rotenone administration
Livia H. Morais et al.
PHARMACOLOGICAL REPORTS (2012)
Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease
Janaina K. Barbiero et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease
Gokhan K. Ulusoy et al.
BRAIN RESEARCH BULLETIN (2011)
The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases
Sandeep Tyagi et al.
JOURNAL OF ADVANCED PHARMACEUTICAL TECHNOLOGY & RESEARCH (2011)
Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease
Alexandre Kreisler et al.
BEHAVIOURAL PHARMACOLOGY (2010)
Chronic treatment with fibrates elevates superoxide dismutase in adult mouse brain microvessels
Guangming Wang et al.
BRAIN RESEARCH (2010)
Progression of Parkinson's Disease Pathology Is Reproduced by Intragastric Administration of Rotenone in Mice
Francisco Pan-Montojo et al.
PLOS ONE (2010)
Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease
Pramod Kumar et al.
BEHAVIOURAL BRAIN RESEARCH (2009)
Anti-Inflammatory Effects of Fibrates: An Overview
Konstantinos Tziomalos et al.
CURRENT MEDICINAL CHEMISTRY (2009)
A highly reproducible rotenone model of Parkinson's disease
Jason R. Cannon et al.
NEUROBIOLOGY OF DISEASE (2009)
Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease
Celine Perier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease:: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not
Alexandre Kreisler et al.
BRAIN RESEARCH (2007)
PPAR:: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases
R. Bordet et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2006)
Peroxisome proliferator-activated receptors and inflammation
Leonardo A. Moraes et al.
PHARMACOLOGY & THERAPEUTICS (2006)
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system
P Remy et al.
BRAIN (2005)
Dysfunction of mitochondrial complex I and the proteasome:: interactions between two biochemical deficits in a cellular model of Parkinson's disease
GU Höglinger et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease α-synuclein fibrillogenesis
S Krishnan et al.
BIOCHEMISTRY (2003)
Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation
TB Sherer et al.
EXPERIMENTAL NEUROLOGY (2003)
Animal models of Parkinson's disease
R Betarbet et al.
BIOESSAYS (2002)
The ligands/activators for peroxisome proliferator-activated receptor alpha (PPAR alpha) and PPAR gamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells
I Inoue et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2001)
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
R Betarbet et al.
NATURE NEUROSCIENCE (2000)
Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators
P Delerive et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions
BI Giasson et al.
SCIENCE (2000)
α-synuclein promotes mitochondrial deficit and oxidative stress
LJ Hsu et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation
S Kanda et al.
NEUROSCIENCE (2000)
Share Paper
